You are here

First in Human Study for PF-06667272

Last updated on December 15, 2017

FOR MORE INFORMATION
Study Location
Pfizer Clinical Research Unit
Brussels, , B-1070 Belgium
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Healthy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy males and female of non-childbearing potential;

- Body Mass Index 17.5-30.5 kg/m2;

- Body weight >50 kg;

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence of history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease (including drug allergies, but excluding untreated, asymptomatic,
seasonal allergies at time of dosing)

NCT03126149
Pfizer
Completed
First in Human Study for PF-06667272

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
First in Human Study for PF-06667272
A Phase 1, Randomized, Double-blind (Sponsor-open), Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06667272 Under Fed And Fasted Conditions, In Healthy Adult Subjects
The current study is the first clinical trial proposed with PF-06667272. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending doses of PF-06667272 under fed and fasted conditions, in healthy adult subjects.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Healthy
  • Drug: PF-06667272
    Single ascending dose of PF-06667272
  • Other: Placebo
    Single dose of placebo
  • Experimental: Cohort 1_Period 1_Active
    Single ascending dose of PF-06667272
    Intervention: Drug: PF-06667272
  • Placebo Comparator: Cohort 1_Period 1_Placebo
    Single dose of placebo
    Intervention: Other: Placebo
  • Experimental: Cohort 1_Period 2_Active
    Single ascending dose of PF-06667272
    Intervention: Drug: PF-06667272
  • Placebo Comparator: Cohort 1_Period 2_Placebo
    Single dose of placebo
    Intervention: Other: Placebo
  • Experimental: Cohort 1_Period 3_Active
    Single ascending dose of PF-06667272
    Intervention: Drug: PF-06667272
  • Placebo Comparator: Cohort 1_Period 3_Placebo
    Single dose of placebo
    Intervention: Other: Placebo
  • Experimental: Cohrot 1_Period 4_Active
    Single ascending dose of PF-06667272
    Intervention: Drug: PF-06667272
  • Placebo Comparator: Cohort 1_Period 4_Placebo
    Single dose of placebo
    Intervention: Other: Placebo
  • Experimental: Cohort 2_Period 1_Active
    Single ascending dose of PF-06667272
    Intervention: Drug: PF-06667272
  • Placebo Comparator: Cohort 2_Period 1_Placebo
    Single dose of placebo
    Intervention: Other: Placebo
  • Experimental: Cohort 2_Period 2_Active
    Single ascending dose of PF-06667272
    Intervention: Drug: PF-06667272
  • Placebo Comparator: Cohort 2_Period 2_Placebo
    Single dose of placebo
    Intervention: Other: Placebo
  • Experimental: Cohort 2_Period 3_Active
    Single ascending dose of PF-06667272
    Intervention: Drug: PF-06667272
  • Placebo Comparator: Cohort 2_Period 3_Placebo
    Single dose of placebo
    Intervention: Other: Placebo
  • Experimental: Cohort 2_Period 4_Active
    Single ascending dose of PF-06667272
    Intervention: Drug: PF-06667272
  • Placebo Comparator: Cohort 2_Period 4_Placebo
    Single dose of placebo
    Intervention: Other: Placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
16
September 5, 2017
September 5, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy males and female of non-childbearing potential;
  • Body Mass Index 17.5-30.5 kg/m2;
  • Body weight >50 kg;

Exclusion Criteria:

  • Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Belgium
 
 
NCT03126149
C0231002
2017-000590-36 ( EudraCT Number )
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Plan to Share IPD: No
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
October 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now